Humanities

Targeting lipoprotein(a) in premature atherosclerotic cardiovascular disease: from pathophysiology to RNA-based therapeutics - a narrative review

Authors

Krzysztof Łukasz Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0002-3438-1967
Paweł Gwałt Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0005-3163-9696
Michał Nowakowski Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0004-9113-4780
Jakub Marzec Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0003-4096-543X
Madgalena Rakuś Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0008-9301-6680
Aleksandra Musioł Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0000-0495-2146

DOI:

https://doi.org/10.12775/JEHS.2026.89.69873

Keywords

lipoprotein(a), premature atherosclerotic cardiovascular disease, RNA-targeted therapies, residual cardiovascular risk

Abstract

Background. Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). In young patients presenting with premature atherosclerotic cardiovascular disease (pASCVD), Lp(a) often emerges as the primary driver of residual cardiovascular risk, persisting despite aggressive low-density lipoprotein cholesterol reduction.

Aim. This review aims to summarize the pathophysiology of Lp(a) in the context of plaque vulnerability, evaluate the limitations of current lipid-lowering therapies, and analyze emerging pharmacological interventions including new RNA-targeted therapies.

Material and methods. A comprehensive search of PubMed-MEDLINE and ClinicalTrials.gov was conducted for articles published in English up to March 2026. Keywords included: lipoprotein(a), Lp(a), Lp(a) lowering, premature ASCVD, siRNA, pelacarsen, and olpasiran. We prioritized randomized controlled trials, meta-analyses, and current societal guidelines.

Results. Traditional lipid-lowering agents, including statins, show no significant effect on Lp(a) levels. Conversely, a novel class of RNA-targeted therapeutics - comprising antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran, zerlasiran, lepodisiran) - demonstrates high efficacy in Phase 1 and 2 trials, achieving near-total (up to 98%) and sustained suppression of Lp(a) concentrations.

Conclusions: The advent of RNA-based therapies represents a significant therapeutic advance in preventive cardiology, transforming Lp(a) from an unmodifiable risk marker into a therapeutic target. While ongoing Phase 3 cardiovascular outcomes trials predominantly enroll older cohorts, Mendelian randomization studies suggest that early initiation of Lp(a) lowering in the pASCVD population may yield the greatest long-term clinical benefits.

References

[1] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2021;42:3227–337. https://doi.org/10.1093/eurheartj/ehab484.

[2] Collet J-P, Zeitouni M, Procopi N, Hulot J-S, Silvain J, Kerneis M, et al. Long-Term Evolution of Premature Coronary Artery Disease. Journal of the American College of Cardiology 2019;74:1868–78. https://doi.org/10.1016/j.jacc.2019.08.1002.

[3] Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. European Heart Journal 2022;43:3925–46. https://doi.org/10.1093/eurheartj/ehac361.

[4] Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. Journal of the American College of Cardiology 2022;80:934–46. https://doi.org/10.1016/j.jacc.2022.06.019.

[5] Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. European Heart Journal 2020;41:2275–84. https://doi.org/10.1093/eurheartj/ehz310.

[6] De Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis. Atherosclerosis 2022;355:40. https://doi.org/10.1016/j.atherosclerosis.2022.06.202.

[7] Mach F, Koskinas KC, Roeters Van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2025;46:4359–78. https://doi.org/10.1093/eurheartj/ehaf190.

[8] Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annual Review of Pharmacology and Toxicology 2024;64:135–57. https://doi.org/10.1146/annurev-pharmtox-031023-100609.

[9] Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis 2022;349:17–35. https://doi.org/10.1016/j.atherosclerosis.2022.04.003.

[10] Heydari M, Rezayi M, Ruscica M, Jamialahmadi T, Johnston TP, Sahebkar A. The ins and outs of lipoprotein(a) assay methods. Archives of Medical Science – Atherosclerotic Diseases 2024;8:128–39. https://doi.org/10.5114/amsad/176653.

[11] Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2022;42. https://doi.org/10.1161/ATV.0000000000000147.

[12] Afanasieva OI, Ezhov MV, Tmoyan NA, Razova OA, Afanasieva MI, Matchin YG, et al. Low Molecular Weight Apolipoprotein(a) Phenotype Rather Than Lipoprotein(a) Is Associated With Coronary Atherosclerosis and Myocardial Infarction. Frontiers in Cardiovascular Medicine 2022;9:843602. https://doi.org/10.3389/fcvm.2022.843602.

[13] Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology 1992;12:6–18. https://doi.org/10.1161/01.ATV.12.1.6.

[14] Rehberger Likozar A, Zavrtanik M, Šebeštjen M. Lipoprotein(a) in atherosclerosis: From pathophysiology to clinical relevance and treatment options. Annals of Medicine 2020;52:162–77. https://doi.org/10.1080/07853890.2020.1775287.

[15] Dzobo KE, Kraaijenhof JM, Stroes ESG, Nurmohamed NS, Kroon J. Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis 2022;349:101–9. https://doi.org/10.1016/j.atherosclerosis.2022.04.004.

[16] Van Der Valk FM, Bekkering S, Kroon J, Yeang C, Van Den Bossche J, Van Buul JD, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation 2016;134:611–24. https://doi.org/10.1161/CIRCULATIONAHA.116.020838.

[17] Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proceedings of the National Academy of Sciences 1997;94:11992–7. https://doi.org/10.1073/pnas.94.22.11992.

[18] Labudovic D, Kostovska I, Tosheska Trajkovska K, Cekovska S, Brezovska Kavrakova J, Topuzovska S. Lipoprotein(a) – Link between Atherogenesis and Thrombosis. Prague Medical Report 2019;120:39–51. https://doi.org/10.14712/23362936.2019.9.

[19] Olmastroni E, Katzmann JL, Galimberti F, Laufs U, Catapano AL. Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association study. European Journal of Internal Medicine 2025;135:47–54. https://doi.org/10.1016/j.ejim.2025.01.021.

[20] Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: Role of oxidative stress. Kidney International 1999;55:1450–61. https://doi.org/10.1046/j.1523-1755.1999.00351.x.

[21] Sabbah N, Jaisson S, Garnotel R, Anglés-Cano E, Gillery P. Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes. Lipids in Health and Disease 2019;18:166. https://doi.org/10.1186/s12944-019-1106-4.

[22] Erlinge D, Tsimikas S, Maeng M, Maehara A, Larsen AI, Engstrøm T, et al. Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques. Journal of the American College of Cardiology 2025;85:2011–24. https://doi.org/10.1016/j.jacc.2025.04.013.

[23] Fang C, Cui LN, Huang DX, Dong FH, Chen JW, Zhao JW, et al. Relationship between lipoprotein(a) and pancoronary plaque vulnerability in patients with acute coronary syndrome: A three-vessel optical coherence tomography study. European Heart Journal 2025;46:ehaf784.344. https://doi.org/10.1093/eurheartj/ehaf784.344.

[24] Duan Y, Zhao D, Sun J, Liu J, Wang M, Hao Y, et al. Lipoprotein(a) Is Associated With the Progression and Vulnerability of New-Onset Carotid Atherosclerotic Plaque. Stroke 2023;54:1312–9. https://doi.org/10.1161/STROKEAHA.122.042323.

[25] Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, Pagidipati NP, et al. Risk Factor Burden and Long‐Term Prognosis of Patients With Premature Coronary Artery Disease. Journal of the American Heart Association 2020;9:e017712. https://doi.org/10.1161/JAHA.120.017712.

[26] Le A, Peng H, Golinsky D, Di Scipio M, Lali R, Paré G. What Causes Premature Coronary Artery Disease? Current Atherosclerosis Reports 2024;26:189–203. https://doi.org/10.1007/s11883-024-01200-y.

[27] Stone NJ, Smith SC, Orringer CE, Rigotti NA, Navar AM, Khan SS, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults. Journal of the American College of Cardiology 2022;79:819–36. https://doi.org/10.1016/j.jacc.2021.12.016.

[28] Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology 2018;72:1141–56. https://doi.org/10.1016/j.jacc.2018.06.046.

[29] Nasoufidou A, Glava A, Mavridou M, Stachteas P, Karagiannidis E, Patoulias D, et al. Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood. Journal of Clinical Medicine 2025;14:6018. https://doi.org/10.3390/jcm14176018.

[30] De Boer LM, Wiegman A, Van Gemert RLA, Hutten BA, Klaassen ILM. The association between lipoprotein(a) levels and ischemic stroke in children: A case–control study. Pediatric Blood & Cancer 2024;71:e31236. https://doi.org/10.1002/pbc.31236.

[31] Wang Z, Zhang J, Tang J. Association between lipoprotein(a) levels, cumulative lipoprotein(a) burden, and cardiovascular outcomes in patients with acute myocardial infarction: A large-scale cohort study. Lipids in Health and Disease 2025;24:383. https://doi.org/10.1186/s12944-025-02800-6.

[32] Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. The Lancet 2018;392:1311–20. https://doi.org/10.1016/S0140-6736(18)31652-0.

[33] Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arteriosclerosis, Thrombosis, and Vascular Biology 2021;41:465–74. https://doi.org/10.1161/ATVBAHA.120.315291.

[34] Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology 2024;18:e308–19. https://doi.org/10.1016/j.jacl.2024.03.001.

[35] Gańko T, Szafrańska W, Kahan W, Poborowska D, Wojaczek M, Bąk E, et al. Effects of physical activity on the cardiovascular system. Quality in Sport 2024;21:53890. https://doi.org/10.12775/QS.2024.21.53890.

[36] Wrzesiński B, Piechocka E, Duda G, Wojtczak P. Sudden Death Amongst People Practicing Competitive Sports (Review Article) 2018. https://doi.org/10.5281/ZENODO.1165406.

[37] Xie S, Galimberti F, Olmastroni E, Carugo S, Catapano AL, Casula M. Effect of lipid-lowering therapies on lipoprotein(a) levels: A comprehensive meta-analysis of randomized controlled trials. Atherosclerosis 2025;408:120420. https://doi.org/10.1016/j.atherosclerosis.2025.120420.

[38] Wołowiec Ł, Pellowska M, Janiak M, Wydeheft L, Grześk G, Zukow W. Bempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk. Journal of Education, Health and Sport 2024;68:55416. https://doi.org/10.12775/JEHS.2024.68.55416.

[39] Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. The Lancet 2015;386:1472–83. https://doi.org/10.1016/S0140-6736(15)61252-1.

[40] Viney NJ, Van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet 2016;388:2239–53. https://doi.org/10.1016/S0140-6736(16)31009-1.

[41] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine 2020;382:244–55. https://doi.org/10.1056/NEJMoa1905239.

[42] Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, et al. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). American Heart Journal 2025;287:1–9. https://doi.org/10.1016/j.ahj.2025.03.019.

[43] Iwakawa H, Tomari Y. Life of RISC: Formation, action, and degradation of RNA-induced silencing complex. Molecular Cell 2022;82:30–43. https://doi.org/10.1016/j.molcel.2021.11.026.

[44] O’Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England Journal of Medicine 2022;387:1855–64. https://doi.org/10.1056/NEJMoa2211023.

[45] Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA 2024;331:1534. https://doi.org/10.1001/jama.2024.4504.

[46] Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA 2024;332:1992. https://doi.org/10.1001/jama.2024.21957.

[47] Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA 2023;330:2075. https://doi.org/10.1001/jama.2023.21835.

[48] Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, et al. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). New England Journal of Medicine 2025;392:1673–83. https://doi.org/10.1056/NEJMoa2415818.

[49] Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA 2023;330:1042. https://doi.org/10.1001/jama.2023.16503.

[50] Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA 2025;333:222. https://doi.org/10.1001/jama.2024.24017.

[51] Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology 2018;3:619. https://doi.org/10.1001/jamacardio.2018.1470.

[52] Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, De Groot E, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New England Journal of Medicine 2019;381:1547–56. https://doi.org/10.1056/NEJMoa1816454.

Journal of Education, Health and Sport

Downloads

PDF

Published

2026-03-28

How to Cite

1.

ŁUKASZ, Krzysztof, GWAŁT, Paweł, NOWAKOWSKI, Michał, MARZEC, Jakub, RAKUŚ, Madgalena and MUSIOŁ, Aleksandra. Targeting lipoprotein(a) in premature atherosclerotic cardiovascular disease: from pathophysiology to RNA-based therapeutics - a narrative review. Journal of Education, Health and Sport. Online. 28 March 2026. Vol. 89, p. 69873. [Accessed 9 April 2026]. DOI 10.12775/JEHS.2026.89.69873.

Download Citation

Issue

Section

Medical Sciences

License

Copyright (c) 2026 Krzysztof Łukasz, Paweł Gwałt, Michał Nowakowski, Jakub Marzec, Madgalena Rakuś, Aleksandra Musioł

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 139
Number of citations: 0